Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00974129

A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

Infantile Hemangioma Tumor Size and C/T Polymorphism Within CTCF Binding Site Six

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
1 Year
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.

Detailed description

This study seeks to examine a potential relationship between CTCF genotype and hemangioma size and growth rate. In addition to the initial visit, patients will return to our clinic for evaluation at two weeks, one month, two months, six months, and one year. At each visit, patients' hemangiomas will be measured and photographed. At one point over the course of evaluation, a blood sample will be taken from each patient for evaluation of C/T polymorphism at CTCF binding site six.

Conditions

Timeline

Start date
2009-09-01
Primary completion
2012-06-01
Completion
2012-06-01
First posted
2009-09-10
Last updated
2014-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00974129. Inclusion in this directory is not an endorsement.

A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas (NCT00974129) · Clinical Trials Directory